1. Scrip
  2. >>Business
  3. >>Deals
  4. >>Deal Watch

Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine

 
• By Joseph Haas

Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.

Deal Watch 2021
• Source: Shutterstock

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Less than two years after going public in a special purpose acquisition corporation merger spearheaded by Foresite Capital, Gemini...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal Watch

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 
• By Joseph Haas, Manas Mishra, and Sushmita Panda

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

 
• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

More from Deals

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 
• By Joseph Haas, Manas Mishra, and Sushmita Panda

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.